Sona Nanotech Inc. (CSE: SONA) announced after market close last night that it has received the go signal from the research ethics board to proceed with the previously approved clinical trials for its saliva-based COVID-19 rapid antigen test. The trials are expected to begin next week.
The clinical trials will seek to test up to 500 emergency room patients suspected of having COVID-19 in Humber River Hospital in Toronto. This process, which is expected to last four to ten weeks, seeks to determine the clinical performance of the saliva test in comparison to RT-PCR among symptomatic patients.
Should the trials yield successful results, additional analytical validation studies from third-party agencies would be commissioned to support any future regulatory submissions.
Sponsored · Antimony Resources
Sona Nanotech Inc. last traded at $1.82 on the CSE.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
